Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Like other serotonergic psychedelics, MiPLA is believed to have a low potential for abuse and psychological dependence, owing to its structural and pharmacological similarities with LSD. These claims are preliminary and based on anecdotal rather than clinical evidence.
MiPLA is believed to have a low potential for dependence based on its structural and pharmacological similarities with LSD and other serotonergic psychedelics. No physical dependence has been documented.
The LD50 of MiPLA is unknown. The toxicity and long-term health effects of recreational MiPLA use have not been studied in any scientific context, and the exact toxic dose remains unknown.
MiPLA may act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance. Adverse psychological reactions including delusions are more likely at higher doses.
The possibility of seizures is extrapolated from rarely reported cases with LSD. Seizures are thought to mainly be a risk in those who are genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment.
MiPLA was originally synthesized by Albert Hofmann at Sandoz Laboratories as part of the foundational structure-activity relationship research into LSD. Eli Lilly and Company subsequently filed a patent for the compound in 1956, with formal publication following in 1961.…
Not specifically prohibited but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) due to structural similarity to LSD.
Classified as a controlled substance under Verzeichnis E point 263 as a defined derivative of lysergic acid. Exempted when used for legitimate scientific or industrial purposes.
Regulated under the Neue Psychoaktive Substanzen Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to distribute, administration to others, and commercial trading are prohibited offenses. Possession is technically illegal but does not carry penalties.
Not specifically scheduled under the Controlled Substances Act. May be prosecuted under the Federal Analogue Act as a structural analogue of LSD when intended for human consumption.
11 sources cited
